Approximately 10-15 infants in Colorado and Wyoming each year are identified with a hemoglobinopathy, most often sickle cell disease.
The Colorado Sickle Cell Treatment and Research Center, established over 40 years ago, and its patient care clinics at the Children's Hospital Colorado and the University of Colorado Hospital on the CU Anschutz Medical Campus is the region's primary source of specialty expertise and facilitation of comprehensive specialty care for both children and adults living with hemoglobinopathies. Basic, clinical and health services research conducted by the Center and its collaborators serves to elucidate the pathophysiology of sickle cell disease, develop and implement treatments and systems of care that prevent or minimize complications and that prolong and improve the quality of life, are supported by funding from the NIH and other Federal agencies, industry, and foundations. Direct patient care is also provided by our Director Kathryn Hassell, MD for adults at University of Colorado Hospital and by Associate Director Rachelle Nuss, MD for pediatric patients at Children’s Hospital Colorado (CHCO). Our Transition Program targets 12 to 26-year-olds to facilitate self-advocacy and health system navigation skills as youth move from pediatric- to adult-oriented healthcare.
The Center is also committed to providing education about sickle cell disease and other hemoglobin disorders to physicians, nurses, other healthcare providers and trainees, and the community at large.
In addition, patients are periodically evaluated for specific therapies such as chronic transfusions, Hydroxyurea, or bone marrow transplantation.
The Governor's Sickle Cell Advisory Board was created to oversee the operations of the Colorado Sickle Cell Treatment and Research Center which was mandated by legislative action in 1974.